A317690 Share Price Performance
₩4,185.00
-14815.00 (-77.97%)
Price ₩4,185.00
Share Price₩4,185.00
A317690 Community Narratives
There are no narratives available yet.
Recent A317690 News & Updates
No updates
QuantaMatrix Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.04k
- Gross Margin
- 38.60%
- Net Profit Margin
- -733.10%
- Debt/Equity Ratio
- 145.8%
QuantaMatrix Inc. Competitors
About A317690
- Founded
- 2010
- Employees
- 91
- CEO
- WebsiteView website
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -1.1%
- 3 Months: 22.2%
- 1 Year: 23.5%
- Year to Date: 30.6%
Over the last 7 days, the market has dropped 1.1%, driven by a loss of 5.7% in the Materials sector. As for the longer term, the market has actually risen by 24% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading